Chronic Kidney Disease

Tirzepatide-treated patients with chronic kidney disease (CKD), obesity, and heart failure with preserved ejection fraction (HFpEF) had improved renal function both by cystatin C and creatinine.

Positive results from an interim analysis of the phase 3 ALIGN study bolstered atrasentan towards receiving accelerated approval for patients with immunoglobulin A nephropathy, a rare condition that can cause kidney failure.

In certain patients with chronic kidney disease (CKD), peritoneal dialysis maintained hemodynamic stability, optimal nutritional status, reduced hospitalization, and lowered diuretics reliance.

Some of these approaches for chronic kidney disease (CKD) include cystatin C, SGLT2 inhibitors, point-of-care testing in remote areas, and acid-lowering medications.

The treatment's expanded indication for chronic kidney disease (CKD) is expected to be available by April 2025.

Additional risk factors included older age and advanced chronic kidney disease (CKD) stage.

Clinical decision support systems based on algorithms have improved outcomes and reduced costs in other health care settings.

The authors suggest future research should consider inflammation and the gut as potential therapeutic targets improve depression in patients with chronic kidney disease (CKD).

Reductions in cerebellar volume were associated with cognitive deficits and lower kidney function in those with CKD.

These findings can lay the foundation for the development of machine learning models in chronic kidney disease (CKD) and kidney failure.

ABO-101 is supported by preclinical data that demonstrated significant reductions in urinary oxalate in PH1 disease models.

Some risk factors for chronic kidney disease (CKD) in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) were renal impairment, delayed diagnosis, and hypertension.

Statin use is not associated with a change in incident chronic kidney disease (CKD) and estimated glomerular filtration rate in adult patients aged 65 and older.

The authors note that transferrin saturation levels may be a modifiable risk factor of chronic kidney disease (CKD) progression and all-cause mortality.

The new indication for semaglutide adds to the long list of conditions that the GLP-1 receptor agonist has been approved for, and provides a new option for high-risk patients with these chronic conditions.

The reduction in cardiovascular end points and the increase in adverse events observed in a clinical trial were largely transportable to trial-eligible chronic kidney disease (CKD) populations from clinical practice.

Patients with methotrexate (MTX)-induced acute kidney injury treated with glucarpidase were 2.70-times more likely to have kidney recovery and recover faster.

The Kidney Disease: Improving Global Outcomes guidelines can provide pharmacists with approaches to minimizing chronic kidney disease progression and complications.

The observational study shows a positive correlation between smoking and chronic kidney disease (CKD) whereas the analyses imply smoking-related covariates may be a factor.

Early diagnosis of chronic kidney disease (CKD) can help optimize treatment and manage the disease to prevent further decline.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.

The results validate the protective benefits of the sodium–glucose cotransporter-2 inhibitors on renal function for those with type 2 diabetes.

Although disease screening reached high-risk patients, uptake was low, necessitating additional incentive to participate in voluntary testing.

Full traditional approval follows accelerated approval of the medication last year.

Pegcetacoplan is a targeted C3 therapy that is intended to regulate excessive activation of the complement cascade.

The indication is for the reduction of proteinuria in adult patients who have primary immunoglobulin A nephropathy and are at risk of disease progression.

Emerging treatments, collaboration between health care providers, and new policy proposals have led to a positive outlook for the future of nonalcoholic steatohepatitis (NASH) and its treatment.

More cost effectiveness data is crucial in advocating for better insurance coverage in the United States.

Benefits of semaglutide on cardiovascular outcomes, such as death, non-fatal myocardial infarction, and non-fatal stoke, were also presented at the session at American Diabetes Association 84th Scientific Sessions.